Taiwan Industry Reports
Industry Type:   Title:  

Biotechnology Services
2024-MarDoc #39854Industry Report (condensed version)US$100
In 2024, Taiwan's biotechnology service industry is poised to navigate through a landscape marked by both challenges and opportunities. Fierce competition from established players in South Korea and China, delays in the clinical trial process for new drugs both domestically and abroad, and the high costs associated with obtaining key raw materials for manufacturing, suggest the industry's growth momentum may experience pressure.
Food Biotechnology Industry
2024-MarDoc #39780Industry Report (condensed version)US$100
The industry is poised to rebound and return to a trajectory of stable growth in the first half of 2024.
Regenerative Medicine
2024-FebDoc #39781Industry Report (condensed version)US$100
Despite the current challenges facing the launch of local cell therapy products in Taiwan and the intense competition faced by surgical suture materials from Chinese players in overseas markets, the domestic market for high-end tissue engineering biomedical material application products remains promising. This is largely due to concerted efforts by domestic players to consolidate and expand markets in China, ASEAN, and emerging markets such as the Middle East and Eastern Europe.
Agricultural Biotechnology
2024-JanDoc #39507Industry Report (condensed version)US$100
Taiwan's agricultural biotechnology industry is forecast to exhibit stable and sustained growth throughout the year 2024.
Drug and Medical Supplies Distribution Industry
2023-DecDoc #39502Industry Report (condensed version)US$100
The industry climate is expected to be slightly favorable in 2023.
Raw Material Medicine Manufacturing
2023-DecDoc #39498Industry Report (condensed version)US$100
The raw materials medicine manufacturing industry is expected to experience a gradual improvement in business conditions in the first half of 2024.
2024 Medical Devices and Equipment Manufacturing
2023-NovDoc #39196Annual Report (condensed version)US$150
Taiwan's medical imaging systems with artificial intelligence will play a key role in exploring the domestic market and ASEAN market. As a result, the industry climate will be better in 2024 than in 2023, which implies a somewhat positive business climate.
Raw Material Medicine Manufacturing
2023-JulDoc #38449Industry Report (condensed version)US$100
Taiwan’s domestic sales and export sales of active pharmaceutical ingredients for epidemics will weaken. Moreover, Chinese firms will improve their competitive edge, while the baseline is high, suggesting the industry climate will ease in the second half of 2023.
Specialty Biotechnology
2023-FebDoc #37630Industry Report (condensed version)US$100
The principal firms in the industry have strengthened the competitive edge by establishing new plants and stores, improving services, expanding into other activities and pursuing multi-dimensional marketing policy to grab business opportunity.
2023 Western Medicine and biopharmaceutical
2022-NovDoc #37097Annual Report (condensed version)US$75
With its enormous biomedicine and information and communication resources, Taiwan is set to become a key partner of major foreign biopharmaceutical companies.
 First  Previous  Next  Last  In  1  /  7  Page  (Find  65  records)

Copyright (c) 2018 All Rights Reserved by
Taiwan Institute of Economic Research
Taiwan Industry Economics Services
Address: 4Fl., 16-8, Tehui St., Taipei, Taiwan
TEL: 886-2-25865000 ext469; FAX: 886-2-25935543